The two most prescribed GLP-1 medications in 2025 are semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Understanding their differences helps you have a more informed conversation with your doctor.
Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — making it a 'dual agonist.' This dual action is why tirzepatide generally produces greater weight loss.
Both are expensive without insurance. Availability varies by country. Semaglutide has been available longer and has broader insurance coverage in many markets. Tirzepatide is newer but rapidly gaining coverage.
This is a decision to make with your doctor. In general: if maximum weight loss is the goal and you're otherwise healthy, tirzepatide may have a slight edge. If you have established cardiovascular disease, semaglutide has more proven cardiovascular benefit data currently.
Getting 100g+ of protein daily on a reduced appetite is hard. Strategic timing makes it more achievable — and more effective for muscle preservation.
Medication helps with appetite. But the mental skills for sustainable weight management — resilience, flexibility, self-compassion — must be built intentionally.
People who share their journey with a community — online or in person — consistently achieve better outcomes. Here's why, and where to find yours.